Insider Selling: Disc Medicine (NASDAQ:IRON) Director Sells $879,190.18 in Stock

Posted by Wayne Rhoads on Oct 21st, 2026

Disc Medicine, Inc. (NASDAQ:IRON – Get Free Report) Director Kevin Bitterman sold 10,994 shares of the firm’s stock in a transaction that occurred on Monday, October 19th. The shares were sold at an average price of $79.97, for a total value of $879,190.18. Following the transaction, the director directly owned 13,312 shares of the company’s stock, valued at approximately $1,064,560.64. This trade represents a 45.23% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kevin Bitterman also recently made the following trade(s):

On Wednesday, October 21st, Kevin Bitterman sold 25,519 shares of Disc Medicine stock. The shares were sold at an average price of $80.23, for a total value of $2,047,389.37.
On Tuesday, October 20th, Kevin Bitterman sold 5,312 shares of Disc Medicine stock. The stock was sold at an average price of $79.95, for a total value of $424,694.40.
On Friday, September 11th, Kevin Bitterman sold 27,136 shares of Disc Medicine stock. The stock was sold at an average price of $70.11, for a total value of $1,902,504.96.
On Friday, September 4th, Kevin Bitterman sold 1,689 shares of Disc Medicine stock. The stock was sold at an average price of $79.96, for a total value of $135,052.44.
On Thursday, September 3rd, Kevin Bitterman sold 5,203 shares of Disc Medicine stock. The shares were sold at an average price of $79.98, for a total value of $416,135.94.
On Wednesday, September 2nd, Kevin Bitterman sold 49,164 shares of Disc Medicine stock. The shares were sold at an average price of $80.17, for a total value of $3,941,477.88.
On Tuesday, September 1st, Kevin Bitterman sold 129 shares of Disc Medicine stock. The stock was sold at an average price of $79.95, for a total value of $10,313.55.

Disc Medicine Stock Down 4.4%

Shares of IRON traded down $3.48 during trading hours on Wednesday, hitting $76.00. The company had a trading volume of 4,638,911 shares, compared to its average volume of 643,026. The stock has a market capitalization of $2.92 billion, a price-to-earnings ratio of -11.55 and a beta of 0.93. The firm has a fifty day moving average price of $71.53 and a 200-day moving average price of $71.39. Disc Medicine, Inc. has a 52-week low of $40.00 and a 52-week high of $99.50. The company has a debt-to-equity ratio of 0.09, a quick ratio of 24.14 and a current ratio of 24.14.

Disc Medicine (NASDAQ:IRON – Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The company reported ($1.54) EPS for the quarter, beating the consensus estimate of ($1.71) by $0.17. On average, equities research analysts forecast that Disc Medicine, Inc. will post -6.61 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on IRON. HC Wainwright reiterated a “buy” rating and issued a $120.00 target price on shares of Disc Medicine in a research note on Thursday, September 10th. Wedbush increased their price target on shares of Disc Medicine from $100.00 to $110.00 and gave the company an “outperform” rating in a report on Monday. Wells Fargo & Company raised their price target on shares of Disc Medicine from $86.00 to $124.00 and gave the company an “overweight” rating in a research report on Tuesday. Jefferies Financial Group restated a “buy” rating and issued a $149.00 price objective on shares of Disc Medicine in a report on Wednesday. Finally, Wall Street Zen lowered shares of Disc Medicine from a “hold” rating to a “sell” rating in a report on Saturday. Eleven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $122.70.

Get Our Latest Research Report on IRON

Institutional Investors Weigh In On Disc Medicine

Institutional investors have recently modified their holdings of the business. BlackRock Inc. bought a new stake in Disc Medicine in the 2nd quarter worth about $180,502,000. Wellington Management Group LLP raised its position in Disc Medicine by 0.3% in the 2nd quarter. Wellington Management Group LLP now owns 1,741,351 shares of the company’s stock worth $127,362,000 after buying an additional 5,975 shares during the last quarter. Assenagon Asset Management S.A. raised its position in Disc Medicine by 191.4% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,119,458 shares of the company’s stock worth $73,280,000 after buying an additional 735,300 shares during the last quarter. Opaleye Management Inc. lifted its stake in Disc Medicine by 103.1% during the 2nd quarter. Opaleye Management Inc. now owns 855,000 shares of the company’s stock valued at $62,535,000 after acquiring an additional 434,000 shares during the period. Finally, Jennison Associates LLC lifted its stake in Disc Medicine by 14.7% during the 1st quarter. Jennison Associates LLC now owns 610,382 shares of the company’s stock valued at $39,028,000 after acquiring an additional 78,303 shares during the period. 83.70% of the stock is owned by hedge funds and other institutional investors.

About Disc Medicine

(Get Free Report)

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biopharmaceutical company focused on developing treatments for serious hematologic diseases. Its research is centered on the biology of red blood cell production and iron homeostasis, with the goal of addressing disorders in which abnormal iron regulation or ineffective erythropoiesis contributes to disease.

The company’s pipeline includes bitopertin, an investigational oral therapy designed to enhance red blood cell production through inhibition of glycine transporter 1.